978-98-3

Usage

Uses

Used in Pharmaceutical Industry:
Progesterone Cyclic 20-(Ethylene Acetal) is used as a GABAA receptor modulator for its potential therapeutic applications in the treatment of various neurological and psychiatric disorders. Its ability to modulate GABAA receptors can lead to anxiolytic, sedative, and anticonvulsant effects, making it a promising candidate for the development of novel therapeutic agents.
Used in Research Applications:
Progesterone Cyclic 20-(Ethylene Acetal) serves as a valuable research tool for studying the role of neurosteroids and GABAA receptors in the central nervous system. It can be used to investigate the mechanisms underlying the modulation of GABAergic neurotransmission and to explore the potential therapeutic benefits of GABAA receptor modulation in various disease states.
Used in Drug Development:
Progesterone Cyclic 20-(Ethylene Acetal) can be employed in the design and development of new drugs targeting the GABAergic system. Its unique structure and functional group may provide insights into the design of more selective and potent GABAA receptor modulators, potentially leading to the discovery of novel therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 2415-36-3 (3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol 
• 108-94-1 cyclohexanone 
• 7381-30-8 2,2,7,7-tetramethyl-3,6-dioxa-2,7-disilaoctane 
• 57-83-0 Progesterone 
• 145-13-1 Pregnenolone 
• 107-21-1 ethylene glycol 
• 40148-10-5 (3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)-2,3,4,7, 8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate 
• 1778-02-5 Pregnenolone acetate 
• 19316-10-0 20,20-ethanediyldioxy-5β-pregnane-3α,6α-diol 
• 116153-06-1 20,20-ethanediyldioxy-3α,6α-bis-(toluene-4-sulfonyloxy)-5β-pregnane 

Downstream Products

• 146201-22-1 4-((phenylthio)methyl)-4-pregnene-3,20-dione 20-ethylene ketal 
• 122723-79-9 Benzoic acid 10,13-dimethyl-17-(2-methyl-[1,3]dioxolan-2-yl)-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-2-yl ester 
• 57-83-0 Progesterone 
• 146276-33-7 (20R,23R,24S)-5α-Dinosterane 
• 146276-37-1 (20R,23R,24R)-5α-Dinosterane 
• 146276-36-0 (20R,23S,24S)-5α-Dinosterane 
• 146276-34-8 (20R,23S,24R)-5α-Dinosterane 
• 146201-25-4 Thiocarbonic acid O-phenyl ester O-[(4S,5S,8R,9S,10R,13S,14S,17S)-4,10,13-trimethyl-17-(2-methyl-[1,3]dioxolan-2-yl)-hexadecahydro-cyclopenta[a]phenanthren-3-yl] ester 

Relevant academic research and scientific papers

Progesterone-pyrazinamide compound, preparation method and anti-cancer application thereof

The invention discloses a progesterone-pyrazinamide compound, a preparation method and anti-cancer application thereof. The general structural formula of the compound is shown as a formula (I). The preparation method disclosed by the invention includes: carrying out Boc amino protection, amidation and Boc removal reaction to obtain an amino acid molecular fragment 3a-o; conducting progesterone C-20 carbonyl protection, A ring C-4 site dimethyl introduction and C-2 oxidation to synthesize an intermediate 6 containing 2, 3-o-dicarbonyl; and finally, constructing a pyrazine ring by utilizing diamino of an amino acid fragment and steroid A ring o-dicarbonyl so as to obtain a target molecule. The progesterone-pyrazinamide compound provided by the invention has inhibitory activity on breast cancer, liver cancer and prostate cancer, and especially has more remarkable inhibitory activity on prostate cancer cells.

COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS

Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-X) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

Method for preparing high quality progesterone

The invention discloses a preparation method of high-quality progesterone, which comprises the following steps: by using pregnenolone as the raw material, sequentially carrying out ketal protection, Oppenauer oxidation and hydrolysis to obtain a progesterone crude product, and recrystalizing to obtain the high-quality progesterone of which the purity is greater than or equal to 99.7% and the single impurity content is less than 0.1%. In the ketal protection process, the pregnenolone and ethylene glycol react in the presence of an organic solvent, triethyl orthoformate and a catalyst; and in the Oppenauer oxidation process, the ketal product obtained by ketal protection reacts with cyclohexanone under reflux conditions in the presence of anhydrous toluene and aluminum isopropoxide. The purity of the prepared progesterone is greater than or equal to 99.7%, the single impurity content is less than 0.1%, and the total weight yield is greater than or equal to 82%, so the method is suitable for industrialized mass production.

PROGESTERONE PHOSPHATE ANALOGS AND USES RELATED THERETO

This disclosure relates to progesterone phophate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or s

Synthesis of E- And Z-isomeric progesterone 3-O-methyloximes

Isomeric E- And Z-3methoxyiminopregn 4-en-20-ones were obtained from progesterone by selective ketalization of 20-oxo group, subsequent oximation of the remaining 3-keto group, removal of the protecting group, and chromatographic separation of isomers.

STEROID ANALOGUES FOR NEUROPROTECTION

Provided are steroid analogues functionalized with polar substituents at the C3 and/or C20 positions of the steroid ring system that exhibit improved water solubility. Also provided are pharmaceutical compositions comprising the steroid analogues and methods using the novel steroid analogues for the treatment and prevention of neurodegeneration in a patient following injury to the central nervous system.

Synthesis of Biological Markers in Fossil Fuels. 7. Selected Diastereomers of 4α-Methyl-5α-stigmastane and 5α-Dinosterane

Efficient routes for the preparation of selected C-23 and C-24 diastereomers of the C30 biological markers 4α-methyl-5α-stigmastane (1) and 5α-dinosterane (2) involved the alkylation of 20-(iodomethyl)-4α-methyl-5α-pregnane with either saturated or α,β-unsaturated esters.The alkylation of (20S)-20-(iodomethyl)-4α-methyl-5α-pregnane with methyl (3R)-3-ethyl-4-methylpentanoate furnished methyl (20R,23ξ,24S)-4α-methyl-5α-stigmastane-23-carboxylate, and a subsequent decarbomethoxylation provided (20R,24R)-1.The alkylation of (20S)-20-(iodomethyl)-4α-methyl-5α-pregnane with methyl (3S)-3,4-dimethylpentanoate led to methyl (20R,23ξ,24R)-4α,24-dimethyl-5α-cholestane-23-carboxylate, and the reduction of this mixture provided principally (20R,23S,24R)-5α-dinosteran-29-ol.The further reduction of the mesylate of this isomer secured (20R,23S,24R)-5α-dinosterane (2a).The application of the same sequence of reactions using methyl (3R)-3,4-dimethylpentanoate led principally to (20R,23R,24S)-5α-dinosterane (2d).The alkylation of (20S)-20-(iodomethyl)-4α-methyl-5α-pregnane with methyl (2ξ)-3,4-dimethyl-2-pentanoate and a subsequent reduction of the ester provided a separable mixture of (20R,23R)- and (20R,23S)-5α-dinoster-24(28)-en-29-ol in a 2.4:1 ratio.The conversion of (20R,23R)-5α-dinoster-24(28)-en-29-ol to the corresponding tert-butyldimethylsilyl ether, reduction of the Δ24(28) bond with hydrogen over platinum oxide, and deprotection gave principally (20R,23R,24R)-5α-dinosteran-29-ol.The further reduction of this alcohol provided (20R,23R,24R)-5α-dinosterane (2b).The application of the same sequence of reactions to (20R,23S)-5α-dinoster-24(28)-en-29-ol provided (20R,23S,24S)-5α-dinosterane (2c).Diastereoselectivity at the C-23 position in these ester alkylations was examined as a function of stereochemistry at both the C-20 and C-24 positions.

A synthesis of C-23 and C-24 diastereomers of 5α-dinosterane

Stereoselective routes for the preparation of C-23 and C-24 diastereomers of the C30 biological marker, 5α-dinosterane (1), involved the alkylation of (20S)-20-(iodomethyl)-4α-methyl-5α-pregnane (7) with either a saturated ester, methyl 3,4-dim

The Trimethylsilyl Cationic Species as a Bulky Proton. Application to Chemoselective Dioxolanation

Use of the "bulky proton" containing reagents trimethylsilyl trifluoromethanesulfonate and 1,2-bisethane to ketalize or acetalize compounds containing two nonconjugated carbonyl groups or one nonconjugated and one α,β-unsaturated carb